WA chowder sold in five states recalled over botulism risk
According to the U.S. Food and Drug Administration (FDA), consumers are told not to eat the 'Smoked Salmon Chowder' and 'Alehouse Clam Chowder' even if they don't look or smell spoiled.
SeaBear initiated the recall after a customer complained about a pouch not being properly sealed. Upon further investigation, the company found a mechanical issue with equipment, which caused the seals to not fully bond and made some pouches leak.
No illnesses have been reported.
The chowders were sold in Alaska, California, Colorado, Oregon and Washington between Oct. 1 and March 14.
Here are the impacted lot codes:
SeaBear Salmon Chowder
64242902 SALCH – Enjoy by: 10/2028
64242912 SALCH – Enjoy by: 10/2028
64242972 SALCH – Enjoy by: 10/2028
64242982 SALCH – Enjoy by: 10/2028
64243042 SALCH – Enjoy by: 10/2028
64243052 SALCH – Enjoy by: 10/2028
64243121 SALCH – Enjoy by: 11/2028
64243131 SALCH – Enjoy by: 11/2028
64243191 SALCH – Enjoy by: 11/2028
64243201 SALCH – Enjoy by: 11/2028
64243651 SALCH – Enjoy by: 12/2028
64250031 SALCH – Enjoy by: 1/2029
64250291 SALCH – Enjoy by: 1/2029
64250301 SALCH – Enjoy by: 1/2029
Alehouse Clam Chowder
64241641 ALECH – Enjoy by: 6/2028
64241643 ALECH – Enjoy by: 6/2028
64241661 ALECH – Enjoy by: 6/2028
64243251 ALECH – Enjoy by: 11/2028
64243261 ALECH – Enjoy by: 11/2028
64250222 ALECH – Enjoy by: 1/2029
64250241 ALECH – Enjoy by: 1/2029
If you have the product at home—don't eat it. Instead, you're asked to call the SeaBear customer service team at 1-800- 645-3474 or email smokehouse@seabear.com for a full refund. SeaBear's customer service hours are Monday-Friday 7 a.m. to -5:30 p.m.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
2 days ago
- USA Today
FDA recalls more than 64,000 pounds of butter over undeclared milk
More than 64,000 pounds of butter have been recalled due to potential undeclared milk allergens, according to the U.S. Food and Drug Administration. Food ingredient company Bunge North America recalled 1,800 cases of its NH European Style Butter Blend that were distributed at 12 centers located across the United States and one in Dominican Republic, a July 14 FDA alert reported. The FDA classified the recall under its second-highest risk warning on July 31 warning that consumption could pose temporary or medically reversible adverse health consequences. USA TODAY has reached out to Bunge North America for comment. Based in Chesterfield, Missouri, Bunge North America is an agribusiness that produces and markets multiple food ingredients including corn, wheat, rice, soybeans and feed peas. Which butter products are recalled? The FDA has issued a recall for 64,800 pounds of Bunge North America's NH European Style Butter Blend with: The product was packaged in white paperboard cases each containing 36 blocks.
Newsweek
3 days ago
- Newsweek
Freeze Dried Fruit Recall Sparks Warning to Customers Across the US
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Doehler Dry Ingredient Solutions, LLC is recalling the Member's Mark brand of freeze-dried fruit variety packs due to fears the product is contaminated with Listeria monocytogenes. Newsweek attempted to reach the company via phone on Friday for comment but could not leave a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. Listeria monocytogenes is a bacterium that poses significant health risks, particularly to pregnant women, newborns, older adults, and individuals with weakened immune systems, according to the FDA. What To Know In the alert, the FDA notes that the products were distributed from July 1, 2025, until July 25, 2025, at Sam's Club retail locations. The states and territories impacted by this recall are: Alabama Arizona California Colorado Connecticut Delaware Florida Georgia Hawaii Iowa Indiana Illinois Idaho Kansas Louisiana Maryland Maine Mississippi Minnesota Missouri Michigan Montana North Carolina North Dakota Nebraska New Hampshire New Jersey New Mexico Nevada New York Ohio Oklahoma Pennsylvania South Carolina South Dakota Tennessee Texas Utah Virginia Wisconsin West Virginia Wyoming Puerto Rico The Member's Mark Freeze Dried Fruit Variety Pack's being recalled are in 15 count boxes with a UPC number of 1 93968 50900 2, the FDA said. The agency added that no illnesses have been reported as of Thursday. The alert has a chart listing the recalled products with corresponding lot code numbers and use by dates for consumers to cross reference. The problem was discovered via "internal testing," the FDA says. A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) What People Are Saying The FDA on its website in part about the incubation period for Listeria infection: "There can be a substantial delay between the time of ingestion of contaminated food and the onset of serious symptoms. The average time from exposure to illness is approximately 30 days, but symptoms can appear as long as 90 days after exposure. It is important for consumers to know that the infection can occur as much as 90 days later, so that they can seek appropriate treatment if they have symptoms of Listeria infection." What Happens Next? Consumers are advised to contact Doehler Dry Ingredient Solutions, LLC's Customer Service via phone at (770) 387-0451 on weekdays from 8 a.m. to 5 p.m. ET with any additional questions, the FDA says. Health authorities continue to emphasize the importance of proper food storage and handling, particularly for ready-to-eat items. The FDA advises consumers to refrigerate perishable foods at and under 40°F, discard recalled products and properly sanitize surfaces that may have contacted suspected contaminated items to prevent the risk of cross-contamination.
Newsweek
3 days ago
- Newsweek
A Doctor's Plea From a Nation Asleep on Brain Disease
Advocates for ideas and draws conclusions based on the interpretation of facts and data. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As a physician who once treated pain, I now endure the unimaginable. Amyotrophic lateral sclerosis (ALS) has left me quadriplegic, dependent on a tracheostomy to breathe and a feeding tube to eat. Diagnosed at 35, my career ended abruptly. My family's story reveals the scale of the coming storm—my father battles Alzheimer's, my uncle succumbed to Parkinson's, and my grandmother to Lewy body dementia. We are not outliers; we represent a silent epidemic. Neurodegenerative diseases are surging, yet our nation slumbers, unaware of the devastation ahead. The public's complacency is by design, built on a statistical illusion. ALS, fatal since 1869, exemplifies this peril. With a median survival of 2-3 years, it strikes about 1 in 300 people in their lifetime, which predicts that over 1 million people now alive in the U.S. will succumb to ALS. Yet, under federal law, it is labeled "rare" because that definition is based on prevalence—a static snapshot of how many people are living with a disease at one time. Because ALS kills its victims so quickly, the number of living patients stays below the 200,000-person "rare" threshold. Its very lethality ensures it is never treated like the mainstream public health crisis it is. This paradox obscures a terrifying forecast: a projected 69 percent global increase in ALS cases by 2040. This illusion of rarity perpetuates a deadly inaction that extends to all brain diseases. Alzheimer's already affects over 7 million Americans and is projected to strike nearly 13 million by 2050, costing our economy $384 billion in 2025—and projected to nearly $1 trillion annually by mid-century. Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Getty Images The failure to confront this crisis stems from a Tale of Two Agencies within the Food and Drug Administration (FDA). In 2017, Congress established the Oncology Center of Excellence (OCE), a dynamic hub that has revolutionized cancer treatment, accounting for 85 percent of all accelerated approvals in the last decade. This success is the result of focused will and resources; National Institutes of Health (NIH) funding for cancer has topped $7.2 billion, compared to $2.8 billion for neuroscience. Neurology has no such center. Lacking an institutional home, it is fragmented, slow, and characterized by a risk aversion unthinkable in oncology. This disparity persists because of the tragic nature of these diseases. In the 1980s, ACT UP activists staged "die-ins" to force a reluctant government to fight AIDS. Patients with ALS, Huntington's, or Alzheimer's cannot mount a similar protest—we are physically silenced and immobilized, unable to "seize the FDA." This vulnerability places a unique moral obligation on our leaders to act proactively on behalf of the voiceless. The new FDA leadership now arrives with bold promises of change, posing a question that haunts everyone touched by an untreatable neurological disease: Will this time be different? Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. vows to "sweep away barriers" and to "figure out new ways ... of accelerating approvals for drugs and treatments that treat rare diseases." FDA Commissioner Marty Makary has several times asked why it takes 10 years for a drug to get to market and proposes a "conditional approval" pathway based on a "plausible mechanism." Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad promised to "take action at the first sign of promise for rare diseases." For the ALS community, these words are now a crisis of credibility. In a disease that has a median survival of 2-3 years, we are asking for regulatory flexibility for a treatment that began its Phase 1 trial in 2011 and was granted FDA Fast Track designation in 2014. As a petitioner on the July 3 citizens' petition for a stem cell therapy known as NurOwn, my community has presented the FDA with a clear test. Ultimately, we are seeking accelerated approval based on new, unprecedented survival data from an expanded access program—data that exceeds the extension of survival of many approved cancer therapies. But the initial request is simpler: invite the sponsor to resubmit its application for a full review. Ours is a request for due process to give a voice to the voiceless—the lowest possible bar for the Trump administration to demonstrate its promised flexibility. A clear, bipartisan solution has already failed once. The Neuroscience Center of Excellence Act, introduced in 2021 to replicate oncology's success for brain disease, stalled in committee. It is time for our leaders to find the political will that has been so catastrophically absent. Congress must immediately revive and pass the Neuroscience Center of Excellence Act. The FDA, in turn, must match its leaders' promises with action by granting our petition a review. The science is poised for breakthroughs, but it is being shackled by a broken system. For those of us on a deadline, this is not a policy debate. It is a death sentence. Awaken now, before this silent storm engulfs us all. The voiceless can't wait. Dr. Shahriar Minokadeh, a former anesthesiologist trained at Johns Hopkins and pain management at UC San Diego, types via an eye-gaze device. The views expressed in this article are the writer's own.
